Fragile X-associated tremor/ataxia syndrome is a late adult onset neurodegenerative disorder that affects individuals who carry a premutation CGG repeat expansion (55-200 CGG repeats) in the 5′ untranslated portion of the fragile X mental retardation 1 (FMR1) gene. Affected individuals display cognitive decline, progressive intention tremor, gait ataxia, neuropathy, psychiatric symptoms, and parkinsonism; the severity of both clinical and neuropathological phenotypes is positively correlated with the extent of the CGG expansion. Overexpression of the expanded CGG repeat messenger RNA results in a direct gain-of-function cellular toxicity that is believed to form the pathogenic basis for fragile X-associated tremor/ataxia syndrome. This mechanism is entirely different from the mechanism giving rise to fragile X syndrome, which is due to transcriptional silencing and consequent loss of FMR1 protein. Much of the research in the field has focused on understanding the link between the pathogenic FMR1 messenger RNA and the potential proteins that interact with it.
HagermanPJ, HagermanRJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004; 74:805–816.
2.
HagermanRJ, LeeheyM, HeinrichsW, . Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001; 57:127–130.
3.
JacquemontS, FarzinF, HallD, . Aging in individuals with the FMR1 mutation. Am J Ment Retard. 2004; 109:154–164.
4.
BrunbergJA, JacquemontS, HagermanRJ, . Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol. 2002; 23:1757–1766.
5.
JacquemontS, HagermanRJ, LeeheyM, . Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003; 72:869–878.
6.
AmiriK, HagermanRJ, HagermanPJ. Fragile X-associated tremor/ataxia syndrome: an aging face of the fragile X gene. Arch Neurol. 2008; 65:19–25.
BrouwerJR, WillemsenR, OostraBA. The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B:782–798.
9.
FuYH, KuhlDP, PizzutiA, . Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991; 67:1047–1058.
10.
VerkerkAJ, PierettiM, SutcliffeJS, . Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991; 65:905–914.
11.
YuS, PritchardM, KremerE, . Fragile X genotype characterized by an unstable region of DNA. Science. 1991; 252:1179–1181.
12.
RousseauF, HeitzD, BiancalanaV, . Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med. 1991; 325:1673–1681.
13.
PierettiM, ZhangFP, FuYH, . Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66:817–822.
14.
BassellGJ, WarrenST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008; 60:201–214.
15.
HagermanRJ, OnoMY, HagermanPJ. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry. 2005; 18:490–496.
16.
LoeschDZ, BuiQM, DissanayakeC, . Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev. 2007; 31:315–326.
17.
HagermanRJ, Berry-KravisE, KaufmannWE, . Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123:378–390.
CoffeySM, CookK, TartagliaN, . Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008; 146:1009–1016.
20.
HagermanPJ. The fragile X prevalence paradox. J Med Genet. 2008; 45:498–499.
21.
AdamsJS, AdamsPE, NguyenD, . Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology. 2007; 69:851–859.
22.
GrecoCM, BermanRF, MartinRM, . Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain. 2006; 129:243–255. Epub 2005 Dec 2005.
23.
GrigsbyJ, BregaAG, JacquemontS, . Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci. 2006; 248:227–233. Epub 2006 June 2015.
24.
HagermanRJ, CoffeySM, MaselliR, . Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A. 2007; 143:2256–2260.
25.
LeeheyMA, Berry-KravisE, GoetzCG, . FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 2008; 70:1397–1402.
26.
LeeheyMA, Berry-KravisE, MinSJ, . Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007; 22:203–206.
27.
TassoneF, AdamsJ, Berry-KravisEM, . CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet. 2007; 144:566–569.
28.
GrecoCM, HagermanRJ, TassoneF, . Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain. 2002; 125:1760–1771.
OrrHT, ZoghbiHY. SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Hum Mol Genet. 2001; 10:2307–2311.
31.
IwahashiCK, YasuiDH, AnHJ, . Protein composition of the intranuclear inclusions of FXTAS. Brain. 2006; 129:256–2. Epub 2005 Oct 2024.
32.
TassoneF, HagermanRJ, TaylorAK, . Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000; 66:6–15.
33.
TassoneF, HagermanRJ, TaylorAK, . Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet. 2000; 91:144–152.
34.
AllenE, HeW, Yadav-ShahM, . A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet. 2004; 114:439–447.
35.
KennesonA, ZhangF, HagedornCH, . Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet. 2001; 10:1449–1454.
36.
EntezamA, BiacsiR, OrrisonB, . Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene. 2007; 395:125–134.
37.
Van DamD, ErrijgersV, KooyRF, . Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res. 2005; 162:233–239.
38.
WillemsenR, Hoogeveen-WesterveldM, ReisS, . The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet. 2003; 12:949–959.
39.
HashemV, GallowayJN, MoriM, . Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet. 2009; 18:2443–2451.
40.
ChangS, BraySM, LiZ, . Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008; 4:256–263.
41.
JinP, ZarnescuDC, ZhangF, . RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron. 2003; 39:739–747.
42.
SofolaOA, JinP, BotasJ, . Argonaute-2-dependent rescue of a Drosophila model of FXTAS by FRAXE premutation repeat. Hum Mol Genet. 2007; 16:2326–2332.
43.
SofolaOA, JinP, QinY, . RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron. 2007; 55:565–571.
ConwayGS, PayneNN, WebbJ, . Fragile X premutation screening in women with premature ovarian failure. Hum Reprod. 1998; 13:1184–1187.
46.
TassoneF, IwahashiC, HagermanPJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 2004; 1:103–105.
47.
DayJW, RanumLP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord. 2005; 15:5–2. Epub 2004 Nov 2026.
48.
RanumLP, DayJW. Pathogenic RNA repeats: an expanding role in genetic disease. Trends Genet. 2004; 20:506–512.
49.
ArocenaDG, IwahashiCK, WonN, . Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet. 2005; 14:3661–3671. Epub 2005 Oct 20.
50.
Berry-KravisE, GoetzCG, LeeheyMA, . Neuropathic features in fragile X premutation carriers. Am J Med Genet A. 2007; 143:19–26.
51.
SoontarapornchaiK, MaselliR, Fenton-FarrellG, . Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol. 2008; 65:495–498.
52.
JinP, DuanR, QurashiA, . Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron. 2007; 55:556–564.
53.
WhiteMK, JohnsonEM, KhaliliK. Multiple roles for puralpha in cellular and viral regulation. Cell Cycle. 2009; 8:1–7.
54.
LiLB, YuZ, TengX, . RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature. 2008; 453:1107–1111.
PushechnikovA, LeeMM, Childs-DisneyJL, . Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc. 2009; 131:9767–9779.
57.
HandaV, SahaT, UsdinK. The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer. Nucleic Acids Res. 2003; 31:6243–6248.
